Striking a Balance Between Speed and Quality to Deliver Next-Generation Therapeutics

Trust a Data-Backed Platform

Bispecific antibodies (BsAbs) are innovative treatments that can target two different parts of a disease, making them more complex than traditional antibodies. Initially created by combining two antibody fragments, these therapies have rapidly advanced and are now being tested for cancer treatment, with many types under clinical trials. FUJIFILM Biotechnologies uses a special system called ApolloX™ to efficiently produce these treatments, focusing on quality and reliable expression. This involves careful design and testing to ensure the treatments are pure and stable. Working with experienced manufacturers is crucial to achieve both speed and quality in production. To learn more about FUJIFILM’s strategies for developing these therapies, you can explore”